Department of Angiology, University Hospital Zurich, Switzerland
Stefano Barco, MD, is a senior staff physician, head of research and head of outpatient clinic at the Department of Angiology of the University Hospital Zurich, Switzerland. He completed a residency in internal medicine (FMH) at the University of Pavia, Italy, a PhD in vascular medicine at the University of Amsterdam, NL, and a residency in vascular medicine at the University of Zurich. Dr. Barco is active in the care of patients with arterial and venous disorders and teaches classes at the undergraduate and graduate levels at different institutions. His primary research interest is in the management of venous thromboembolism. His projects have been funded by the Swiss National Fonds and by the German Federal Ministry of Education and Research. He has been granted the habilitation (venia legendi) in Switzerland and Italy. He is a member of the World Thrombosis Day steering committee, in the nucleus of the European Society of Cardiology “Working Group on Pulmonary Circulation and Right Ventricular Function”, co-chair of the ISTH subcommittee “Factor XI and the Contact System”, and a member of the International Consortium for Health Outcome Measures for VTE. Dr. Barco is the recipient of the 2022 Swiss Angiology Society Award, 2021 Scientist Award of the Walter and Gertrud Siegenthaler Foundation, 2021 Bayer Thrombosis Prize, and 2014 Bonizzoni Award (Ferrata-Storti Foundation), as well as of the GTH, ESC, SISET, and ISTH Early Career Awards. He serves as Associate Editor for 'Thrombosis Research', 'Haemostaseologie', and 'VASA-European Journal of Vascular Medicine', and as Editorial Board Member for the 'Journal of Thrombosis and Hemostasis'.
CCB Vascular Centre Frankfurt
Rupert Bauersachs is a clinical angiologist and haemostaseologist at the Vascular Centre of the CCB in Frankfurt, which he joined in 2021. From 2003-2021 he was head of the Department of Vascular Medicine at the Klinikum Darmstadt, and from 1999-2003 he was acting director of the Department of Vascular Medicine at Goethe University in Frankfurt. Professor Bauersachs is board certified for Vascular Medicine, Internal Medicine, Haemostaseology, Phlebology and Diabetology. His broad scientific and clinical focus includes the development of new antithrombotic agents for the treatment of thromboembolic disorders, thrombophilia, heparin-induced thrombocytopenia, ischemia and reperfusion. One of his main concerns and interests is the improvement of the care of specific, vulnerable patient groups that are commonly neglected in large clinical trials, for example elderly, frail patients, patients with impaired renal function, patients with cancer or pregnant women. His professorship thus focuses on Vulnerable Individuals and Populations in Thrombosis and Hemostasis (VIP-TH). Professor Bauersachs has conducted the largest prospective trial in pregnant women at increased risk for venous thromboembolism, the EThIG-Study. This study, enrolling more than 800 high-risk pregnant women, showed that a risk-stratified administration of low molecular weight heparin is both safe and effective in pregnancy. With the interdisciplinary infrastructure available at the CTH and the translational research program, detailed analyses and follow-up studies are possible to further improve the management and outcome of pregnant women with venous thromboembolism.
Cardiovascular Research Institute Maastricht (CARIM)
Since 2002, Hugo ten Cate is professor of Clinical Thrombosis and Hemostasis at the Cardiovascular Research Institute (CARIM), University Medical Center Maastricht. He previously worked at the University of Amsterdam and as a researcher at Harvard Medical School. Nationally and internationally, he is one of the most productive and successful scientists in the field of Hemostaseology, which is shown in more than 200 articles published in leading journals. In Mainz, he will establish a research group and continue his experimental and translational studies with colleagues and young scientists of the CTH.
Dr. Stepan Gambaryan is currently Professor of Cytology and Histology, Biological faculty, of S. Petersburg State University (Russia) and Scientist at the Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, S. Petersburg, Russia. Previously, he worked for 20 years with Dr. Suzanne Lohmann and Professor Ulrich Walter as invited research scientist of the SFB 355 “Heart failure” (1993-2014) and SFB688 “Cardiovascular cell-cell interactions” (2006-2013) at the Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, Germany. His main areas of research are the mechanisms of action of NO, cGMP, cAMP and their interactions with other intracellular pathways in cardiovascular cells. He has published more than 100 articles in this area. As Guest Scientist in Mainz since September 2015, Dr. Gambaryan joined the team of PD Dr. Kerstin Jurk and Prof. Ulrich Walter to study the interaction of platelet stimulatory and inhibitory pathways at the level of phosphoproteomics. In particular, the interaction of important platelet adhesion receptors and cAMP/cGMP signaling will be studied.
University Medical Center Hamburg (UKE)
Thomas Renné has been Professor of Clinical Chemistry and Laboratory Medicine at the University Medical Center Hamburg-Eppendorf (UKE) since 2013. After studying medicine and chemistry in Mainz, he worked at the University Hospital Würzburg and Karolinska Institute, Stockholm, Sweden. His experimental and translational work focuses on interactions between blood coagulation and inflammatory processes. He was able to show that factor XII driven contact phases have a central function for pathological thrombosis, although it has no importance for hemostasis e.g. in injuries. He is particularly interested in the procoagulant and proinflammatory mediators polyphosphate (an inorganic polymer) and "neutrophil extracellular traps" (NETs). His work has led to nearly 200 publications in prestigious journals. By networking with the experimental and clinical working groups of the CTH, the subject area of thrombo-inflammation will be further developed and strengthened.
